Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask the Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
FAQs
Advertising
Report Store
UsernamePublicRestriction
Tags:
BioPharmaceutical

BioShield II May Revive Big Pharma’s Interest In Biodefense

  • News

Executive Summary

The proposed "BioShield II" legislation is reviving big pharma's interest in the biodefense industry, McKenna Long & Aldridge Partner Frank Rapoport maintained March 3 at Equity International's Homeland & Global Security Summit in Washington, D.C

You may also be interested in...



Pfizer Names Bush Cabinet Veteran Principi To Head Government Affairs

Former Veterans Affairs Secretary Anthony Principi will replace Pfizer VP-Government Relations Kenneth Bowler as head of the company's government affairs staff effective March 15

Pfizer Names Bush Cabinet Veteran Principi To Head Government Affairs

Former Veterans Affairs Secretary Anthony Principi will replace Pfizer VP-Government Relations Kenneth Bowler as head of the company's government affairs staff effective March 15

FDA “Rapid-Action” Team, Pre-Emption Included In GOP Bioterror Bill

The Senate leadership's biodefense bill for 2005 would direct FDA to create a special compliance unit to help prevent shortages of vaccines

Table

View full table

Topics

Tags:
BioPharmaceutical
UsernamePublicRestriction

Register

ID1130879

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By